NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- David Shook, MD
Nkarta, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Institute of Haematology, Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
- St. Vincent'S Hospital
Sydney, New South Wales, Australia
- Royal Brisbane and Woman'S Hospital
Brisbane, Queensland, Australia
- Peter Maccallum Cancer Center
Melbourne, Victoria, Australia
- Colorado Blood Cancer Institute
Denver, Colorado, United States
- the Cleveland Clinic Foundation
Cleveland, Ohio, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 20 Aug 2021
- Primary completion
- 31 Mar 2025
- Completion
- 31 Dec 2038
- Last update posted
- 20 Apr 2026
- Registered enrollment
- 150
- Registry id
- NCT05020678
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.